AstraZeneca PLC (NASDAQ:AZN – Get Free Report) declared a Semi-Annual dividend on Thursday, July 25th, Zacks reports. Investors of record on Friday, August 9th will be paid a dividend of 0.49 per share on Monday, September 9th. The ex-dividend date of this dividend is Friday, August 9th.
AstraZeneca has raised its dividend payment by an average of 1.2% per year over the last three years. AstraZeneca has a payout ratio of 41.7% meaning its dividend is sufficiently covered by earnings. Analysts expect AstraZeneca to earn $4.68 per share next year, which means the company should continue to be able to cover its $1.97 annual dividend with an expected future payout ratio of 42.1%.
AstraZeneca Trading Down 0.5 %
Shares of AstraZeneca stock opened at $78.13 on Friday. AstraZeneca has a 52-week low of $60.47 and a 52-week high of $80.86. The stock’s 50-day simple moving average is $78.54 and its 200 day simple moving average is $71.92. The stock has a market capitalization of $242.25 billion, a P/E ratio of 38.30, a P/E/G ratio of 1.42 and a beta of 0.45. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.70 and a current ratio of 0.89.
Analysts Set New Price Targets
A number of brokerages recently issued reports on AZN. Argus boosted their price objective on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. The Goldman Sachs Group assumed coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target on the stock. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Barclays upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, BMO Capital Markets upped their price target on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $88.00.
Get Our Latest Research Report on AZN
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
- Five stocks we like better than AstraZeneca
- Retail Stocks Investing, Explained
- Why Call Options Volume for These 2 Stocks Spiked Together
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 7/22 – 7/26
- What is the Nikkei 225 index?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.